CD4 and neoplasm: We then studied with in vivo cell-depletion experiments the role of CD8+ and CD4+ T cells in the tumor rejection phase and found the importance of CD8+ and of both CD4+ and CD8+ T lymphocyte subsets in the eradication of K7M2 (Fig. 2B) and WEHI-164 tumors (Fig. 2A), respectively.